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Abstract 
   
Objective. To determine autonomic dysfunction (AD) differences in patients with relapsing remitting 
multiple sclerosis (pwRRMS) and progressive MS (pwPMS).  
Methods. Composite autonomic scoring scale (CASS) and heart rate variability (HRV) were performed in 
40 pwRRMS and 30 pwPMS.  
Results. pwPMS had a significantly higher sudomotor index and total CASS score compared to pwRRMS 
(p<0.001 and p<0.001, respectively). Disease duration positively correlated with sudomotor index and 
total CASS (rs=0.409, p<0.001 and rs=0.472, p<0.001, respectively), while the Expanded Disability Status 
Scale (EDSS) positively correlated with sudomotor index and total CASS (rs=0.411, p<0.001 and rs=0.402, 
p=0.001, respectively) in all patients. Type of multiple sclerosis (pwRRMS or pwPMS) corrected for age, 
sex and disease duration, was a statistically significant predictor of CASS value (B=1.215, p=0.019). 
Compared to pwRRMS, pwPMS had a significantly lower standard deviation of NN intervals (SDNN), low 
frequency (LF), and high frequency (HF), during both the supine and tilt-up phases (all p-values <0.006). 
pwPMS had a significantly lower LF/HF (p=0.008) during tilt-up. 
Conclusion. There is a significant difference in autonomic function in pwRRMS and pwPMS; with pwPMS 
having a higher burden of AD, which is particularly evident for sweating dysfunction.   
Significance. Further research is needed to establish whether parasympathetic and sudomotor 
dysfunction may serve as markers of progressive MS.  
 
Key words: multiple sclerosis, relapsing-remitting; multiple sclerosis, progressive; autonomic nervous 
system; composite autonomic scoring scale; heart rate variability. 
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Highlights 
 MS disease type is an independent predictor of dysautonomia.  
 There is a difference in pattern of dysautonomia in pwRRMS and pwPMS.  
 Sweating dysfunction is common in MS, particularly in advanced disease.  
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Introduction 
 
Multiple sclerosis (MS) is an idiopathic demyelinating disorder of the central nervous system. It most 
commonly affects young individuals, between 20 and 40 years-of-age and represents the leading cause of 
non-traumatic neurologic disability in young adults (Edmonds et al., 2010). Although the exact etiology is 
unknown, there is a complex interaction between several environmental factors and a distinct genetic 
susceptibility which results in demyelinating lesions, the pathological hallmark of MS (Compston and 
Coles, 2008). The pathogenesis of the disease is marked by the production of autoreactive lymphocytes 
that cross the blood-brain barrier and enter into the central nervous system causing demyelination, 
axonal loss and, ultimately, neurodegeneration (Wu and Alvarez, 2011).  
The natural history of MS seems to be divided into two distinct phases. First is the relapsing-remitting 
phase, characterized by bouts of acute exacerbation of disease activity. Pathologically, this is correlated 
with central nervous system (CNS) inflammation. The second phase is determined by a slow but steady 
progression in neurologic deficit, associated with CNS degeneration (Compston and Coles, 2008). The 
differentiation between these two phases of the disease (on an individual level) can sometimes be 
difficult. It is based on a temporal relationship between relapses from which patients typically experience 
partial or complete recovery, while simultaneously undergoing a progression of irreversible central 
nervous system dysfunction. Deciding whether increased disability is a consequence of a partially 
recovered relapse or a sign of the progressive form of the disease is still a troublesome task for the 
clinician. Onset of a progressive disease course in MS is defined by the onset of insidiously worsening and 
irreversible decline in neurologic function, regardless of the absence or presence of relapses; and, which 
cannot be explained purely with a step-wise worsening, associated with ongoing relapses (Tutuncu, 2012). 
Although somewhat simplistically dichotomized, this distinction between relapsing-remitting MS (RRMS) 
and progressive MS (PMS) does reflect disease evolution in a real life setting. In most patients, MS will 
begin with a relapsing-remitting course, with a smaller number of patients having progressive disease 
from the start, primary progressive MS (PPMS). Approximately 50% of RRMS patients will go on to 
develop secondary progressive MS (SPMS), in about nineteen years’ time (Confavreux and Vukusic, 2006). 
Altogether, 80% of RRMS patients will ultimately develop SPMS after an average of 25 years. About 20% 
of patients will remain in the relapsing-remitting form of the disease, ultimately experiencing a reduced 
number of relapses as time passes (Kremenchutzky et al., 2006). It is not clear which patients will 
eventually progress to SPMS, but frequent relapses and the number of demyelinating lesions seem to 
carry a certain risk for future progression (Bhsteh et al., 2016).  
When the progressive phase occurs, there are many clinical similarities in patients with SPMS and PPMS, 
leading to a unifying theory that SPMS and PPMS can be considered as a distinct disease entity when 
compared to RRMS. This observation is mainly related to patients’ age and the time it takes them to reach 
 5 
certain disability milestones, such as impaired walking or walking with a cane, referenced to the time that 
passed from one particular milestone to the other. The expanded disability status scale (EDSS), a 
standardized tool for neurologic disability assessment in MS, reflects this. Specifically, it takes patients 
with SPMS and PPMS about the same amount of time to reach EDSS 6 from EDSS 4, around 12 years. 
Bearing this in mind, RRMS can be regarded as a 'younger' disease that has not yet had time do develop 
into the progressive type; while SPMS and PPMS represent disease which 'got older' or was, in fact, 'old' 
to begin with, respectively (Confavreux and Vukusic, 2006). The diagnosis of RRMS in clinical practice 
begins with the clinically isolated syndrome (CIS), which represents the first clinical episode suggestive of 
MS. The course of the disease is marked by an acute exacerbation and periods of clinical stability, 
characterized as relapsing-remitting. On the other hand, when the disease progresses after an initial 
relapsing-remitting period, the disease is characterized as secondary progressive. Lastly, when there is 
progression of neurologic disability from the start, the disease is considered primary progressive in its 
nature. Therefore, the diagnosis of PMS is actually made retrospectively and the difference between 
RRMS and PMS is based on clinical evidence.   
Little is known about how different disease courses affect different non-motor symptoms of MS, impeding 
prognosis and disease management. In a recent meta-analysis, for example, it has been shown that 
cognitive impairment significantly differs between RRMS and PMS (Johnen et al., 2017). These results 
imply that patients with PMS (pwPMS) display severe degrees of cognitive impairment and need more 
specialized disease management than patients with RRMS (pwRRMS). 
Knowing that autonomic dysfunction (AD) in MS can affect virtually every end organ that the autonomic 
nervous system (ANS) innervates, the lack of studies on AD in MS – in particular studies investigating 
differences between RRMS and PMS – is surprising (Adamec and Habek, 2013). The most extensively 
investigated part of the ANS is the cardiovascular autonomic system, due to its convenience for testing. In 
general, ANS research can be divided into research regarding patient reported symptoms (usually using a 
variety of questionnaires) and assessment of ANS function/dysfunction in a controlled setting. In 
structural disorders of the ANS (dysautonomia caused by different pathological processes in the central or 
peripheral nervous system), a great discrepancy between patient reported symptoms and laboratory 
findings can be observed. One study has shown that even patients with severe sympathetic dysfunction 
(orthostatic hypotension with a decrease in systolic blood pressure more than 60 mm Hg from baseline 
during a head-up tilt table test) can be completely asymptomatic during the head-up tilt table test in up to 
one third of cases (Arbogast, 2009). Therefore, in patients with structural ANS disorders, like MS, 
autonomic dysfunction should actively be searched for with laboratory tests. 
In recent years there has been an upsurge in cardiovascular ANS laboratory investigations, involving 
patients with MS. It has been demonstrated that AD is frequent in MS and is present even in the earliest 
stages of the disease (CIS) with parasympathetic dysfunction present in 5%, sympathetic in 42.6% and 
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sudomotor in 32.7% of patients (Habek et al., 2016). Furthermore, there is emerging evidence suggesting 
that certain ANS disorders, like postural orthostatic tachycardia syndrome, may serve as significant 
predictors of early conversion from CIS to MS (Habek et al., 2017). Several studies, using standardized 
tests of cardiovascular autonomic function (heart rate and blood pressure responses to Valsalva 
maneuver and heart rate response to deep breathing), have suggested a distinct pattern of AD in different 
phases of the disease. In the CIS stage there is predominant sympathetic dysfunction (both adrenergic and 
cholinergic), with sparing of the parasympathetic system (Crnošija et al., 2016). A similar finding was 
observed in pwRRMS, where adrenergic sympathetic dysfunction was higher in patients with active MS 
compared to healthy controls or stable patients (Flachenecker et al., 2001).  In contrast, parasympathetic, 
but not sympathetic dysfunction, increases with disease duration significantly correlating with an increase 
in clinical disability (Flachenecker et al., 2001). In order to confirm this distinct pattern of autonomic 
involvement in MS, and due to lack of studies specifically assessing the difference in autonomic function 
in relapsing-remitting and progressive stages of the disease, we aimed to to determine differences in AD 
in pwRRMS and pwPMS.  
 
 
Materials and methods 
 
Patients 
This was a prospective study performed from September 2015 to September 2016 that included 
consecutive patients diagnosed with RRMS and PMS; with the PMS group including patients with both 
PPMS and SPMS. The patients were recruited during their regular follow-up visits at the Outpatient Clinic 
of the Department of Neurology, University Hospital Center Zagreb – a tertiary medical center and a 
referral center for autonomic nervous system disorders. Patients were diagnosed with RRMS and PPMS 
based on the 2010 revision of the McDonald criteria (Polman et al., 2011). SPMS was defined based on 
the criteria by Lublin et al. (2014). The patients were examined by two of the authors (MH and IA), 
neurologists with more than five years of experience dealing with individuals with MS, and they 
performed the EDSS examinations. The EDSS is a standard tool used to evaluate neurologic disability in 
patients with MS (Kurtzke, 1983). 
Exclusion criteria included significant cardiac or pulmonary disease and medication with known influence 
on the autonomic nervous system (anticholinergics, antihypertensives, beta blockers, diuretics, 
antiarrhythmics, sympathomimetics, parasympathomimetics).  
The ethical committee of the University Hospital Center Zagreb approved the study. All participants 
signed informed consent. 
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Autonomic nervous system testing 
ANS testing was performed in a quiet and dimly lit room. Quantitative Sudomotor Axon Reflex Test 
(QSART) was performed with the Q-Sweat (WR Medical Electronics Co Maplewood, MN, USA) (Novak, 
2011). Afterwards, heart rate and blood pressure responses to the Valsalva maneuver were measured, 
followed by heart rate response to deep breathing (Novak, 2011). Finally, the tilt table test was 
performed, measuring the blood pressure response to passive tilt with a duration of 10 minutes (Task 
Force Monitor (TFM), CNSystems Medizintechnik AG, Austria) (Freeman, 2006). The Composite 
Autonomic Scoring Scale (CASS) was utilized to quantify AD (Low, 1993). The CASS is a score that is further 
divided into three parts or indices – adrenergic, cardiovagal and sudomotor.  Blood pressure response to 
the Valsalva maneuver and passive tilting determine the adrenergic index. The Valsalva index, heart rate 
response to Valsalva maneuver, and heart rate response to deep breathing determine the cardiovagal 
index. Finally, QSART results give rise to the sudomotor index. The adrenergic, cardiovagal and sudomotor 
indices of the CASS score are useful in identifying adrenergic, cardiovagal and sudomotor disturbances of 
the ANS, respectively. This approach enables the diagnosis of limited or restricted forms of the autonomic 
failure, beside the generalized autonomic failure alone (Low et al., 2013). Autonomic dysfunction is 
defined as a CASS score greater than 0. Grading of AD is based on the severity of findings in each index. 
The adrenergic index ranges from 0 to 4; the cardiovagal index from 0 to 3; and the sudomotor index from 
0 to 3. When the three indices are tallied, the total CASS score may range from 0 to 10. Results are 
interpreted as normal (total CASS score = 0) or abnormal (total CASS > 0). The abnormalities can range 
from mild autonomic failure (total CASS score 1–3), moderate (total CASS score 4–6), or severe (total CASS 
score 7–10) (Low, 1993).  
 
Heart rate variability analysis 
Heart rate variability (HRV) analysis was performed as previously described (Habek et al., 2016). Power 
spectral analysis of HRV was performed with the Kubios HRV 2.2 software (Department of Applied Physics, 
University of Eastern Finland, Kuopio, Finland) using time and frequency-domain methods. The variables 
autoregressive spectral estimation method was used in spectral analysis of the frequency domain. Data 
that were used for the HRV analysis were recorded with the TFM, with a sampling frequency of 1000 Hz. 
The data were subsequently inspected and edited for any missing data. Data quality was ensured by using 
the medium artefact correction option and Smoothness priors-based detrending approach (Lambda = 
500) (Tarvainen et al., 2014). Heart rate variability was analyzed in 5-minute intervals of beat-to-beat data 
recorded during the testing (Malik et al., 1996). HRV analysis of the supine phase data set was performed 
on the most stable 5-minute interval for every patient (‘s’ variables). HRV analysis of the tilted data set 
was performed on the most stable 5-minute interval between the 1st and 9th minutes of testing (‘t’ 
variables). High-frequency (HF) (0.15–0.4 Hz) power of RR intervals, expressed in absolute units, was used 
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as a cardiovagal activity index (Sztajzel 2004). Low frequency (LF) (0.04–0.15 Hz) power of RR intervals, 
expressed in absolute units, was used as an index of combined sympathetic and parasympathetic cardiac 
activity (Sztajzel 2004). HF expressed in normalized units (HFnu), was utilized as an index of 
parasympathetic branch modulation of the ANS (Malik et al., 1996). Low to high frequency ratio (LF/HF) 
was utilized as a marker of sympathovagal balance (Malik et al., 1996). The time domain analysis 
parameter, standard deviation of NN intervals (SDNN), was utilized as a marker of overall HRV (Malik et 
al., 1996). 
 
 
Outcomes 
The primary aim was to determine differences in AD between pwRMMS and pwPMS. Specifically, 
differences in total CASS, as well as adrenergic, cardiovagal and sudomotor indices, were assessed for the 
two groups.  
In addition, a correlation analysis was performed to see the level of association between clinical 
parameters (EDSS and disease duration) and ANS parameters (CASS indices). Finally, a multiple linear 
regression model was used in order to examine the influence of sex, age, disease duration and MS type 
(RRMS or PMS) on the likelihood that pwMS will have AD measured with the total CASS. 
The secondary outcome was to determine differences in neural regulation of heart rate in pwRRMS and 
pwPMS by assessing HRV parameters.  
 
 
Statistical analysis 
Statistical analysis was performed using the IBM SPSS software, version 20. The Kolmogorov–Smirnov test 
was applied to test whether the data have a normal distribution. Differences in the distribution of 
qualitative variables were determined with the χ2 test (sex, frequency of QSART response, frequency of 
orthostatic hypotension), while the differences in quantitative variables were determined with the use of 
a parametric t-test (age, RSA, Valsalva index) or a non-parametric Mann–Whitney test (disease duration, 
EDSS, CASS). To determine the correlation between the variables, the Spearman correlation method was 
used (disease duration, EDSS, CASS). A multiple linear regression model, based on four predictors (age, 
sex, disease duration and MS type (RRMS or PMS)), was used in order to determine significant predictors 
for the presence of AD, measured with the total CASS score. The multiple regression model, based on four 
predictors (age, sex, disease duration and MS type (RRMS or PMS)), was also used in order to determine 
significant predictors for HRV variables. For the predictors in the multiple regression models, p values less 
than 0.05 were considered as significant. For analysis that included multiple comparisons on the same 
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data set, p values corrected with the Bonferroni correction were considered as significant (number of 
comparisons=4, Bonferroni corrected p-value=0.05/4=0.0125). 
 
 
Results 
 
Patients 
During the study period, 40 pwRRMS and 30 pwPMS were enrolled. There were 6 patients with PPMS and 
24 patients with SPMS. Patients’ characteristics are presented in Table 1. Patients in the RRMS group were 
significantly younger (p<0.001), and the RRMS group had a shorter disease duration (p<0.001) and lower 
EDSS values (p<0.001).  
 
Autonomic testing results 
Total CASS was available for 39 pwRRMS. In one patient, the adrenergic index could not be calculated due 
to technical difficulties during testing. The CASS results for pwRRMS are presented in Table 2. Autonomic 
nervous system dysfunction, a CASS score greater than 0, was present in 59.0% of pwRRMS. Sympathetic 
dysfunction was noted in 35.9%, cardiovagal in 2.5% and sudomotor in 35.0% of patients (Fig. 1). 
In pwPMS, the total CASS score was available for 23 patients, as the blood pressure values in 7 patients 
during the Valsalva maneuver could not be properly evaluated, due to artifacts. The CASS results for 
pwPMS are presented in Table 2, with frequency of specific systems involved presented in Figure 1. ANS 
dysfunction, a CASS score greater than 0, was present in 91.3% of patients. Sympathetic dysfunction was 
noted in 60.9%, cardiovagal in 20.0% and sudomotor in 73.3% of patients (Fig. 1). 
 
Primary outcome 
pwPMS had a significantly higher sudomotor index and total CASS compared to pwRRMS (p<0.001 and 
p<0.001, respectively). Furthermore, disease duration positively correlated with sudomotor index and 
total CASS in all patients (rs=0.409, p<0.001 and rs=0.472, p<0.001, respectively). The correlation between 
total CASS and disease duration was moderate. The EDSS positively correlated with sudomotor index and 
total CASS in all patients (rs=0.411, p<0.001 and rs=0.402, p=0.001, respectively). The correlation between 
total CASS and EDSS was moderate. Although differences in CASS between pwRRMS and pwPMS were 
found, all scores were compatible with mild autonomic failure (Low, 1993).  
When comparing results of individual autonomic tests, between the two groups, pwPMS had significantly 
lower respiratory sinus arrhythmia (RSA) compared to pwRRMS (14.33±6.06 vs. 22.40±7.36, respectively; 
p<0.001). Also, pwPMS had significantly more pathological sweating responses on QSART compared to 
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pwRRMS (Table 3). There was no significant difference between the two groups regarding Valsalva index 
values and frequency of orthostatic hypotension on tilt-up (p=0.246 and p=0.129, respectively). 
A multiple regression model was used to predict the presence of AD measured with the total CASS, based 
on age, sex, disease duration and MS type (RRMS or PMS). The multiple regression model statistically 
significantly predicts the total CASS variable (F=7.792, p<0.001), with a R2=0.354. MS type (RRMS or PMS), 
corrected for age, sex and disease duration, was a statistically significant predictor for the presence of AD 
measured with the total CASS (B=1.215, p=0.019). Age, sex and disease duration were not identified as 
independent predictors for the presence of AD measured with the total CASS (p=0.167, p=0.718 and 
p=0.089 respectively). 
 
Secondary outcome 
We included 40 pwRRMS and 28 pwPMS in the HRV analysis. Two pwPMS were not included in the 
analysis, as they were in the tilted position less than five minutes due to development of orthostatic 
symptoms. Values of HRV parameters for each group are presented in Table 4. 
Compared to pwRRMS, pwPMS had significantly lower SDNN, LF, and HF during both supine and tilt-up 
phases (all p-values <0.006). There were no significant differences in LF/HF when supine, but pwPMS had 
significantly lower LF/HF (3.18±2.63 vs. 5.65±4.71, p=0.008) during tilt-up. In order to see which 
parameters (age, sex, disease duration, MS type (RRMS or PMS)) are possibly significant predictors for 
HRV variables, we performed a multiple regression analysis, the results of which are presented in 
supplementary Table 1. 
 
Discussion 
The results of this study have revealed two important aspects of AD in MS: 1) there is a difference in 
pattern of AD in pwRRMS and pwPMS; and 2) sweating dysfunction is common in MS, particularly in 
advanced disease. 
The first important finding is the difference in pattern of AD in pwRRMS and pwPMS. The pwPMS had 
significantly higher CASS scores when compared to pwRRMS. This signifies a more pronounced ANS 
involvement in pwPMS, as a higher CASS score conveys greater involvement of the ANS. Previous studies 
have shown AD to be present in 60% of patients with early MS (Crnošija et al., 2016; Habek et al., 2016). 
Specifically, sympathetic dysfunction was most commonly present in patients with CIS, followed by 
sudomotor dysfunction with parasympathetic dysfunction present in just about 5% of patients (Habek et 
al., 2016). The present study has shown similar results for pwRRMS, with autonomic involvement being 
present in the majority of patients (Fig. 1). Sympathetic dysfunction was noted in 35.9% and cardiovagal in 
2.5% of patients. These results suggest that in the active, inflammatory stage of the disease, the 
sympathetic system is most commonly affected with a relative sparing of the parasympathetic system. 
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Previous studies associated this preferential involvement of one arc of the ANS with the presence of 
demyelinating lesions in the brainstem and involvement of the locus coeruleus, resulting in disruption of 
norepinephrine synthesis (Polak et al., 2011). Another possible explanation was provided by Flachenecker 
et al. (2001), who argued that the sympathetic nervous system may be closely related with a disorder of 
immune regulation, which is the pathophysiological basis of MS, while the parasympathetic dysfunction 
may be caused by the disease itself. This interesting hypothesis is in line with the results of our study, 
showing predominant adrenergic affection in pwRRMS; with a similar pattern observed in a previous 
study on patients with CIS (Habek et al., 2016). Furthermore, as MS progresses, more of the 
parasympathetic damage becomes evident, with a fifth of the pwPMS having parasympathetic 
dysfunction in the current study.  
The HRV analysis part of the study has shown that pwPMS have significantly lower SDNN, LF, and HF 
during both the supine and tilt-up phases, compared to pwRRMS. This represents an overall decrease of 
HRV in pwPMS, with a decrease of cardiovagal activity, as well as combined sympathetic and 
parasympathetic cardiac activity. These results are in concordance with CASS results in pwPMS, which also 
show a higher degree of both adrenergic and cardiovagal dysfunction, compared to pwRRMS. 
Furthermore, 20% of pwPMS featured a positive cardiovagal index compared to 2.5% of pwRRMS. This 
finding was also evident on HRV analysis with lower values of HF, an index of cardiovagal activity. These 
results differentiate pwPMS from patients with CIS as well, since patients with CIS were found to have 
sympathovagal imbalance, mainly due to diminished sympathetic output; further emphasizing the 
development of parasympathetic injury in pwPMS (Habek et al., 2016). On the other hand, pwPMS had 
significantly lower LF/HF during tilt-up, which indicates lower adrenergic activity during orthostatic 
provocation, thus revealing blunted sympathetic reactivity. 
One of the clinical consequences of these observations is limited exercise capacity in pwMS, due to the 
blunted heart rate and blood pressure response to exercise (Senaratne et al., 1984). As the current study 
has demonstrated, a significant number of patients with MS have disturbed cardiac autonomic reflexes, 
and disruption of these reflexes may cause an inadequate cardiac autonomic control during endurance 
exercise (Hansen et al., 2013). The importance of physical activity has been reinforced by results of a 
recent study, showing that high-intensity and resistance training actually improves quality of life in 
patients with MS (Zaenker et al., 2017). Therefore, limited exercise capacity in individuals with MS, due to 
disturbed cardiovascular autonomic reflexes, can severely affect patients' abilities to properly perform 
physical rehabilitation – an essential aspect of MS treatment. 
The second important finding observed was that sweating dysfunction was present in 35.0% of pwRRMS 
and 73.3% of pwPMS. These results are of importance as they demonstrate that sweating dysfunction is 
common in MS, particularly in advanced disease. There have only been a few previous studies assessing 
sudomotor function in MS (Davis et al., 2005; Habek et al., 2016; Saari et al., 2009). Patients with MS 
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seem to have a lower sweating response when compared to healthy controls; without a disease specific 
pattern (Saari et al. 2009). Similar to our findings, thermoregulatory hypohydrosis was associated with 
increased neurologic disability (Saari et al., 2009). Although QSART has been traditionally used as a 
marker of peripheral cholinergic postganglionic nerve affection, its values can be abnormal even with 
preganglionic lesions, as demonstrated in a previous study (Davis et al., 2005). On the other hand, QSART 
may reflect peripheral nerve affection in MS. Namely, the notion of MS as a pure central nervous system 
disorder has recently come into question. Jende et al. (2017) have demonstrated peripheral nerve lesion 
involvement in pwMS using high resolution MRI. These findings may provide a new pathophysiological 
concept of MS, which has yet to be established.  
Another aspect of this observation is the clinical manifestation which thermoregulatory abnormalities 
may cause. Detecting sweating dysfunction in individuals with MS is of importance, as inadequate 
thermoregulation can cause reoccurrence of previous symptoms – the Uhthoff’s phenomenon. Uhthoff’s 
phenomenon represents transient worsening of symptoms with increased body temperature, due to a 
disturbance of nerve conduction. It is thought to result from heat induced closure of voltage-gated 
sodium channels, leading to inadequate action potential depolarization (Frohman et al. 2013). Therefore, 
inadequate body temperature regulation can lead to transient neurologic worsening in pwMS. Also, the 
inability to cool down properly can lead to poor exercise tolerance, which can limit physical activity 
(Huang et al., 2014).  
Finally, the multiple regression model showed that type of MS (RRMS or PMS) corrected for age, sex and 
disease duration was a statistically significant predictor for the presence of AD measured with the total 
CASS. This finding is interesting in the light of recent ideas that both sympathetic and parasympathetic 
ANS function and/or dysfunction have an influence on inflammatory and neurodegenerative pathways in 
MS (Racosta and Kimpinski, 2016). Whether these observed changes are drivers of the inflammation 
and/or neurodegeneration, or they are just a consequence of MS itself, remains to be elucidated. 
The limitation of this study may be selection bias, as patients were recruited in a tertiary medical center 
and a referral center for diseases of the ANS. However, the patients were not part of a preselected study 
group and were consecutively included, thus being representative of a population of individuals with MS. 
In conclusion, results of this study demonstrate that more than half of pwRRMS experience AD, with the 
frequency rising to 90% in pwPMS. There is a significant difference in autonomic function in pwRRMS and 
pwPMS, with pwPMS having a higher burden of AD. Furthermore, a substantial number of tested patients 
had sudomotor dysfunction - significantly more often in the pwPMS, a part of ANS testing frequently 
neglected. Moreover, HRV analysis has shown to be overall lower in pwPMS compared to pwRRMS, with a 
blunted sympathetic reactivity. These results suggest that autonomic affection is an intricate part of MS 
activity. It is known that ANS has an important role in the regulation of the immunological system via 
adrenergic and cholinergic receptors on the immune cells (Kohm and Sanders 2001). Further research is 
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needed to asses a possible causative association between immunological derangement present in MS and 
ANS function. Given the effect that AD can have on physical activity and thermoregulation, specific care 
should be taken to address any autonomic symptoms and signs in MS patients – especially in the 
progressive stage.  
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Tables 
 
Table 1. Patients’ characteristics, disease duration and EDSS. 
 pwRRMS pwPMS p-value 
Total number 40 30  
Female/Male 33/7 17/13 0.031a 
Mean age 35.45±9.15 48.03±10.58 <0.001*b 
Mean disease duration 
(days) 
1980.60±2246.50 4774.23±2283 <0.001*c 
Median EDSS (range) 1.25 (0 to 3.5) 6.5 (3.5 to 8.0) <0.001*c 
pwRRMS- patients with relapsing-remitting multiple sclerosis. pwPMS- patients with progressive multiple 
sclerosis. EDSS-Expanded Disability Status Scale, * - statistically significant, a χ2 test, b t-test, c Mann-
Whitney test, Bonferroni corrected p-value = 0.0125     
  
Table 2. Autonomic testing results for relapsing remitting and progressive multiple sclerosis patients. 
Autonomic dysfunction pwRRMS pwPMS p-value 
N Median  Range N Median  Range  
Adrenergic index 39 0 0 to 3 23 1 0 to 3 0.029 
Cardiovagal index 40 0 0 to 1 25 0 0 to 2 0.018 
Sudomotor index 40 0 0 to 2 30 1 0 to 3 <0.001* 
CASS 39 1 0 to 5 23 3 0 to 6 <0.001* 
pwRRMS- patients with relapsing-remitting multiple sclerosis. pwPMS- patients with progressive multiple 
sclerosis. CASS-Composite Autonomic Scoring Scale, * - statistically significant, Mann-Whitney test, 
Bonferroni corrected p-value = 0.0125   
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Table 3. Comparison of frequency of different types of QSART responses between relapsing-remitting and 
progressive multiple sclerosis patients. 
 QSART result 
pwRRMS 
N 
pwPMS 
N 
p value 
Forearm 
Normal 37 22 
0.001 
Hypohydrosis 0 5 
Hyperhydrosis 2 0 
Pers. sweating 0 1 
Anhydrosis 0 2 
Proximal leg 
Normal 31 12 
0.004 
Hypohydrosis 5 9 
Hyperhydrosis 1 1 
Pers. sweating 3 3 
Anhydrosis 0 5 
Distal leg 
Normal 30 13 
0.004 
Hypohydrosis 2 4 
Hyperhydrosis 4 2 
Pers. sweating 4 4 
Anhydrosis 0 7 
Foot 
Normal 34 16 
0.003 
Hypohydrosis 4 6 
Hyperhydrosis 0 0 
Pers. sweating 1 0 
Anhydrosis 1 8 
     
pwRRMS- patients with relapsing-remitting multiple sclerosis. pwPMS- patients with progressive multiple 
sclerosis. QSART- quantitative sudomotor axon reflex test. Pers.-persistent. Dist.-distal, χ2 test, Bonferroni 
corrected p-value = 0.0125   
 
Table 4. Comparison of HRV analysis data for patients with relapsing remitting multiple sclerosis (RRMS) 
and progressive multiple sclerosis patients (PMS) 
 
 pwRRMS  pwPMS 
 Mean Median St. Dev Min Max  Mean Median St. Dev Min Max 
LF supine 759.43 436.00* 1432.48 68.00 8935.00  198.11* 129.50 208.66 11.00 888.00 
HF supine 892.70 397.00* 1316.41 79.00 5981.00  230.79* 154.00 281.84 6.00 1382.00 
LF/HF supine 1.18* 0.93 1.14 0.13 6.77  1.29* 1.25 0.85 0.24 4.24 
HFnu supine 53.09* 51.70 17.27 12.90 87.70  48.56* 44.40 15.29 19.00 80.50 
SDNN supine 37.67* 32.25 21.52 15.40 121.00  20.53* 17.90 9.70 6.30 52.40 
LF upright 521.28* 393.50 400.13 62.00 1583.00  161.43 73.00* 216.15 4.00 928.00 
HF upright 199.95 74.50* 330.18 15.00 1750.00  87.32 33.00* 135.91 1.00 666.00 
LF/HF upright 5.65* 4.52 4.71 0.36 17.87  3.18 2.59 2.63 0.33 11.43 
HFnu upright 23.41* 18.10 15.76 5.30 73.40  34.37 27.90 20.39 8.00 75.20 
SDNN upright 27.33* 23.35 13.33 11.80 84.80  16.39 13.05 8.81 3.40 40.10 
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pwRRMS- patients with relapsing-remitting multiple sclerosis. pwPMS- patients with progressive multiple 
sclerosis. LF-low frequency. HF-high frequency. HF.nu-High frequency normalized units. SDNN- standard 
deviation of all normal RR intervals, mean* parametric distribution, median* non-parametric distribution 
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Figures 
 
Figure 1. Frequency of autonomic, parasympathetic, sympathetic and sudomotor dysfunction in relapsing-
remitting and progressive multiple sclerosis patients with CASS, cardiovagal index, adrenergic index and 
sudomotor index, respectively. CASS-composite autonomic scoring scale. Blue – relapsing-remitting 
multiple sclerosis. Red – progressive multiple sclerosis. 
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Supplementary Table 1: Multiple regression analysis, performed for HRV variables, * 
presents statistically significant predictors, p value=0.05 
HRV variable 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B 
Std. 
Error Beta 
LF_supine           
(Constant) 1366.800 788.536   1.733 0.088 
Age -19.235 14.314 -0.197 -1.344 0.184 
Sex 184.743 324.266 0.072 0.570 0.571 
Disease 
duration 
-0.030 0.062 -0.067 -0.475 0.636 
MStype -204.099 364.322 -0.089 -0.560 0.577 
HF_supine           
(Constant) 1892.511 694.028   2.727 0.008 
Age -22.276 12.599 -0.241 -1.768 0.082 
Sex 131.123 285.402 0.054 0.459 0.648 
Disease 
duration* 
0.151 0.055 0.362 2.759 0.008 
Mstype* -748.772 320.657 -0.346 -2.335 0.023 
LF/HF_supine           
(Constant) 0.722 0.726   0.994 0.324 
Age 0.011 0.013 0.125 0.834 0.407 
Sex 0.019 0.299 0.008 0.062 0.951 
Disease 
duration 
-9.886E-
05 
0.000 -0.248 -1.724 0.090 
MStype 0.232 0.336 0.112 0.692 0.492 
HF.nu_supine           
(Constant) 66.631 11.206   5.946 0.000 
Age -0.080 0.203 -0.056 -0.392 0.697 
Sex -2.762 4.608 -0.074 -0.599 0.551 
Disease 
duration* 
0.002 0.001 0.383 2.784 0.007 
Mstype* -10.552 5.177 -0.317 -2.038 0.046 
SDNN_supine           
(Constant) 66.662 12.228   5.452 0.000 
Age* -0.486 0.222 -0.290 -2.191 0.032 
Sex 0.044 5.028 0.001 0.009 0.993 
Disease 
duration 
0.001 0.001 0.163 1.278 0.206 
MStype* -14.273 5.649 -0.363 -2.526 0.014 
LF_upright           
(Constant) 1471.268 224.533   6.553 0.000 
Age* -8.756 4.076 -0.268 -2.148 0.036 
Sex* -191.897 92.334 -0.225 -2.078 0.042 
Disease 
duration 
-0.005 0.018 -0.033 -0.273 0.786 
MStype* -279.780 103.739 -0.366 -2.697 0.009 
HF_upright          
(Constant) 580.455 185.004   3.138 0.003 
Age 0.037 3.358 0.002 0.011 0.991 
Sex -123.635 76.078 -0.202 -1.625 0.109 
Disease 
duration 
0.026 0.015 0.245 1.779 0.080 
MStype* -207.625 85.476 -0.378 -2.429 0.018 
LF/HF_upright           
(Constant) 13.945 2.596   5.372 0.000 
Age* -0.131 0.047 -0.367 -2.782 0.007 
Sex -1.471 1.068 -0.158 -1.378 0.173 
Disease 
duration 
0.000 0.000 -0.196 -1.547 0.127 
MStype -0.333 1.199 -0.040 -0.278 0.782 
HF.nu_upright           
(Constant) -5.042 11.364   -0.444 0.659 
Age* 0.554 0.206 0.348 2.688 0.009 
Sex 3.060 4.673 0.074 0.655 0.515 
Disease 
duration* 
00.002 0.001 0.335 2.691 0.009 
MStype -1.570 5.250 -0.042 -0.299 0.766 
SDNN_upright           
(Constant) 59.114 7.851   7.529 0.000 
Age -0.186 0.143 -0.168 -1.302 0.198 
Sex* -7.961 3.229 -0.276 -2.466 0.016 
Disease 
duration 
0.001 0.001 0.104 0.837 0.406 
Mstype* -11.707 3.628 -0.453 -3.227 0.002 
 
